| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 3.4B | +2% |
| Operating Income | 972.9MM | -12% |
| Operating Expenses | 2.5B | - |
| Net Income | 1.2B | +15% |
| R&D | 1.2B | +9% |
| G&A | 737.7MM | +15% |
| Interest Expense | 18.3MM | +3% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss Additional presentations cover progress in novel genetic medicine delivery systems and immune response modulation TARRYTOWN, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data across its genetic medicines portfolio will be presented at the American Soc
Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Over the past year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a significant stake in the...
Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Regeneron Pharmaceuticals said on Monday it seeks to defend against U.S. Department of Justice's complaint that alleged the company misreported the average sales price of its macular degeneration drug Eylea. "Reimbursing credit card service fees to distributors is not a price concession and does not affect EYLEA's price," Regeneron said in a statement, adding that it considered the complaint to be "meritless". The DOJ last week, in a complaint filed in federal court in Boston, alleged the drug...
"Reimbursing credit card service fees to distributors is not a price concession and does not affect EYLEA's price," Regeneron said in a statement, adding that it considered the complaint to be "meritless". The DOJ last week, in a complaint filed in federal court in Boston, alleged the drugmaker failed for years to report how it paid hundreds of millions of dollars to subsidize Eylea purchases by reimbursing drug distributors for credit-card processing fees.
Regeneron Pharmaceuticals said on Monday the U.S. Justice Department's complaint against the company misreporting the average sales price for its macular degeneration drug Eylea is "meritless" and it plans to defend this case in court. The Justice Department last week had accused Regeneron of manipulating Medicare's drug-pricing process by inflating the average sales price for its Eylea drug.
While corporate venture arms are commonplace among pharmaceutical companies, the new fund announced Monday is Regeneron’s first.